ABCL

AbCellera is a clinical-stage antibody company, not a profitable business, and the headline numbers say so plainly: FY2025 revenue of $75.1M against a $217M operating loss (-289% operating margin) and a $146M net loss. The eye-catching +160.6% revenue growth is a mirage — it was driven almost entirely by licensing & royalty revenue jumping from $1.0M to $46.9M (per the MD&A table), while recurring research fees barely moved ($26.3M → $27.2M) and milestones shrank. The longer history makes the volatility undeniable: revenue ran $375M–$485M in 2021–2022 on COVID antibody economics, then collapsed to ~$29–38M before this one-off licensing bump. A 32.8x P/S on lumpy, partnership-driven revenue is not a meaningful valuation anchor; this stock is priced on pipeline optionality, full stop.

What keeps this from an outright avoid is the balance sheet. Liabilities/equity is just 0.40x, equity is $967M, and current assets of $728M tower over $64.3M of current liabilities. Even though headline cash is only $129M, the company is burning ~$131M of operating cash a year, and the large current-asset base (cash plus marketable securities) implies multiple years of runway before dilution becomes urgent — capex was also cut 45% to $42.8M, signaling the heavy GMP-facility build is moderating. Management's own framing is 'we expect to incur losses for the foreseeable future' and success 'depends on our ability to develop and monetize a drug,' so the durability of the franchise is entirely forward-looking.